CVS Health received positive news when Medicare finalized a 2.5% payment increase to providers, significantly better than the initially proposed 0.09% increase. This $13 billion boost to insurers like CVS's Aetna unit improves profitability outlook. Trading at 11x forward earnings compared to peers at 15-20x, CVS appears undervalued with potential to reach $90-$100 per share, supported by 3.4% dividend yield and expected earnings growth.

Health insurance stocks are currently beaten down due to political concerns and rising claims costs, but present long-term investment opportunities. UnitedHealth Group and Oscar Health are highlighted as undervalued plays poised for recovery as the sector rebounds in 2026, supported by structural growth in U.S. healthcare spending.

The article argues that AI is transitioning from being viewed as a bubble to being recognized as a genuine productivity booster, with growing evidence from major institutions and real-world applications. The author recommends BlackRock Technology and Private Equity Term Trust (BTX), a closed-end fund yielding 9.3% and trading at a 14.9% discount to NAV, as a way to gain exposure to both private AI companies like Anthropic and established tech giants.

The S&P 500 and Nasdaq edged up slightly on April 7, 2026, while the Dow slipped amid geopolitical tensions over Iran's ceasefire deadline. Apple declined on foldable iPhone delay concerns, while health insurers and Broadcom surged on positive news. Market sentiment remained cautious as investors rotated toward safer assets like U.S. Treasuries.

The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing greater rate predictability for insurers. Major healthcare stocks surged on the positive announcement.

UnitedHealth Group (UNH) surged 8.04% to $303.98 on Tuesday following a favorable CMS Medicare Advantage reimbursement decision. The stock is testing the psychological $300 resistance level, though technical analysis suggests the next phase may be a grind rather than straight-line recovery. Bulls cite cost-cutting and AI-driven efficiency gains ahead of April 21 earnings, while bears worry about projected membership losses of 1.3-1.4 million in Medicare Advantage for 2026.

U.S. stock futures rose on Tuesday as investors awaited Trump's deadline regarding Iran's Strait of Hormuz. UnitedHealth Group surged 6.86% following favorable Medicare Advantage payment rates, while Silo Pharma jumped 45.31% on a patent approval for PTSD treatment. Phillips 66 declined 0.75% due to reported losses from rising oil prices amid geopolitical tensions. The S&P 500 and Nasdaq Composite posted modest gains, with analysts maintaining optimistic outlooks for 2026 despite ongoing market volatility.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a reliable choice for passive income investors. The ETF recently underwent reconstitution, removing 22 stocks including AbbVie, Cisco Systems, and Valero, while adding 25 stocks including UnitedHealth Group, Procter & Gamble, and Abbott Laboratories. The ETF reduced exposure to energy and materials sectors while increasing healthcare and tech exposure. With a dividend yield of approximately 3.5%, it offers more than three times the S&P 500 average yield.

The article recommends three dividend stocks for long-term investors: Philip Morris International, which is expanding into smoke-free nicotine products with strong growth; Pfizer, offering a high 6.2% dividend yield despite being down 55% from highs and facing headwinds in obesity drugs; and UnitedHealth Group, a health insurer down 58% from highs but expected to rebound with strong earnings growth driven by an aging U.S. population.

The article examines the three highest-yielding stocks in the Dow Jones—Verizon (5.6% yield), Chevron (3.3% yield), and UnitedHealth Group (3.3% yield)—concluding that none represent a clear buying opportunity. Verizon offers reliable income but faces high debt and slow dividend growth; Chevron is well-managed but may be overpriced due to temporary oil price spikes; UnitedHealth is an industry leader but faces regulatory headwinds and earnings volatility.

The Schwab U.S. Dividend Equity ETF (SCHD) completed its annual reconstitution, adding UnitedHealth and Abbott Laboratories while removing AbbVie. These changes increased the fund's healthcare sector allocation from 15.4% to 18.9%, making it the second-largest sector weighting. The new holdings have a higher average dividend growth rate (9.4% vs 8.6%), which should generate more income and potentially higher total returns for investors over time.

The article recommends two healthcare stocks for long-term investors with $500 to invest. Pfizer, trading at 9x forward earnings, has faced revenue declines post-COVID but is positioning for growth through oncology acquisitions and entry into the obesity drug market. UnitedHealth Group, trading at 15x forward earnings, struggled with underestimated healthcare costs but has implemented cost-cutting measures and AI optimization to recover.